Psychiatry

Carrie Jardine leads a discussion on varying prior authorization policies for alternative therapies for treatment-resistant depression along with implications to patients.

Dr. Levine is joined by Dr. Sanjay Mathew to talk about some exciting treatments in the pipeline for psychiatric disorders.

Key opinion leaders in the management of ADHD comment on where they anticipate using viloxazine and other nonstimulants in the ADHD treatment landscape.

Greg Mattingly, MD, and David W. Goodman, MD, discuss the recent approval of viloxazine in children and its clinical profile in the pediatric and adult populations in ADHD.

The approval expands the indication for Qelbree to all patients with ADHD aged 6 years and older, and provides adult patients their first novel non-stimulant option in 20 years.

A study shows the Visceral Sensitivity Index could help identify anxiety and health-related quality of life burden in patients with IBS or IBD.

Key opinion leaders discuss navigation through challenges with appropriate coding for the treatment of patients with treatment-resistant depression.

Carrie Jardine and Martin Rosenzweig, MD, share considerations for benefit design in behavioral health.

There were key aspects that differed in the gut microbiota between patients with major depressive disorder and the healthy control group.

Palliative care programs were challenging during the COVID-19 pandemic.

Females were disproportionately affected by some of the restrictions put in place in the early stages of the COVID-19 pandemic.

Experts in behavioral health discuss overcoming barriers to access for alternative therapies for TRD, including the Risk Evaluation and Mitigation Strategy (REMS) requirement for intranasal esketamine.

Dr Patricia Ares-Romero and Dr Martin Rosenzweig discuss treatment strategies for TRD, including alternative therapies, and explain barriers within the health care system that inhibit access.

Patients with inflammatory bowel disease are at an increased risk of developing depression.

Drs Samuel Nordberg, Patricia Ares-Romero, and Martin Rosenzweig share considerations for effective care delivery for patients with TRD.

Experts in behavioral health discuss therapeutic options for TRD and considerations for defining value.

While it is known that ASD is linked to altered gut microbiota, there is little research into the altered bacterial species.

The digital software program was significantly beneficial and tolerable among patients who used it over 6 weeks, according to new findings.

Dr Samuel Nordberg and Carrie Jardine discuss barriers to accessing care for patients with TRD and provide insight on addressing these concerns to achieve optimal care.

Dave Bellevue of The Oxymorrons joins Steve to talk about his journey to mental health advocacy.

There is a need for new medications for depression to overcome high rates of treatment resistance.

Dr Samuel Nordberg discusses methods for identifying patients in need of an alternative therapy for TRD at the health system level.

The treatment represents the only FDA approved orally dissolving sublingual film for this patient population.

Patricia Ares-Romero, MD, reviews the frequency of TRD diagnosis and common risk factors, and Martin Rosenzweig, MD, explores patient identification and economic burden of disease.

Samuel Nordberg, PhD, discusses challenges with the definition and identification of TRD in the clinical setting.